Please assess the completion status of the following clinical trial:

Trial Title: SRL (Sirolimus) Withdrawal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male and female recipients of all races, ≥ 18-75 years of age~2. Patients who underwent primary living or deceased donor liver transplantation ≥ 3 years (previous to screening ) and on ≥ 3 months of stable SRL monotherapy~3. Recipient of single organ transplant only~4. Liver transplant for non-immune, non-viral (no hepatitis B or hepatitis C virus unless currently non-viremic) causes~5. Ability to provide informed consent and to comply with the study protocol of IS withdrawal.~Exclusion Criteria:~1. Inability or unwillingness to provide informed consent~2. Acute cellular rejection within 12 months prior to enrollment~3. Viral (viremic hepatitis B virus \[HBV\] or hepatitis C virus \[HCV\]) or immune-mediated liver disease (Autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis) history~4. Abnormal liver function tests: Direct bilirubin ≥ 1 mg/dL; (\[ALT, AST, GGT\] or alkaline phosphatase \[AlkPhos\] ≥ 2x \[ULN\]); 5) Abnormal graft histology at enrollment: a) ≥ Grade 2 inflammation or stage 2 fibrosis; b) Acute or Chronic Rejection; c) De-novo Autoimmune Hepatitis; d) inflammation of \>50% of portal tracts; e) Other pathology not-specified but deemed high risk per the PI and pathologist; 6) Ongoing or recurrent substance abuse~7) Retransplantation or combined liver-other organ 8) Human Immunodeficiency Virus(HIV) co-infection 9) Glomerular Filtration Rate (GFR)\<30 ml/min by estimated glomerular filtration rate (\[eGFR\]-\[MDRD-4\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single-arm study Sirolimus Withdrawal (Type: EXPERIMENTAL): SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).